SBIR Phase II: Molecular Interaction Measurement System: A Label-free Detection Platform.

Period of Performance: 01/01/2009 - 12/31/2009


Phase 2 SBIR

Recipient Firm

Ridge Diagnostics Inc.
7862 Via Coscoja
Carlsbad, CA 92009
Principal Investigator


This Small Business Innovation Research (SBIR) Phase II project is to build upon the feasibility of using MIMS technology to determine the presence and measure the concentration of multiple protein biomarkers (specifically autoantibodies) within a single sample. In order to achieve our primary objective in Phase II, PHB proposes to produce a new highly-sensitive and stable MIMS system prototype for clinical use. We will develop a prototype disposable, reliable, easy to use biochip cassette with limited potential for biohazard exposure. To reduce the need for off-chip processing, PHB will implement a cartridge- based fluidic channel to remove blood cells. We will develop specific attachment strategies for antibodies and/or F(ab)2 fragments of antibodies that enable the efficient capture of antigens to be used as targets for autoantibodies. This will eventually lead to the development of reverse capture arrays for identification of autoantigens against which autoAb expression may be used to differentiate between normal and disease states. We will optimize the protein printing methodology, and blocking protocols to enable the optical interference detection system to provide reproducible results in molecular binding reactions on a multiplicity of nanostructured protein chips. We will evaluate the performance of the optimized substrate and platform in real-time with a representative set of antibody targets. Our initial focus will be a panel consisting of Thyroperoxidase antibody, TSH receptor antibodies and